Literature DB >> 29555782

Oncolytic Reovirus Inhibits Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in a TLR3-Dependent Manner.

Yuki Katayama1, Masashi Tachibana1, Nozomi Kurisu1, Yukako Oya1, Yuichi Terasawa1, Hiroshi Goda1, Kouji Kobiyama2,3, Ken J Ishii2,3, Shizuo Akira4,5, Hiroyuki Mizuguchi1,6,7, Fuminori Sakurai8,9.   

Abstract

Oncolytic reovirus, which possesses 10 segments of dsRNA genome, mediates antitumor effects via not only virus replication in a tumor cell-specific manner, but also activation of antitumor immunity; however, the mechanism(s) of reovirus-induced activation of antitumor immunity have not been fully elucidated. Recent studies have demonstrated that overcoming an immunosuppressive environment in tumor-bearing hosts is important to achieve efficient activation of antitumor immunity. Among the various types of cells involved in immunosuppression, it has been revealed that myeloid-derived suppressor cells (MDSCs) are significantly increased in tumor-bearing hosts and play crucial roles in the immunosuppression in tumor-bearing hosts. In this study, we examined whether reovirus inhibits the immunosuppressive activity of MDSCs, resulting in efficient activation of immune cells after in vivo administration. The results showed that splenic MDSCs recovered from PBS-treated tumor-bearing mice significantly suppressed the Ag-specific proliferation of CD8+ T cells. In contrast, the suppressive activity of MDSCs on T cell proliferation was significantly reduced after reovirus administration. Reovirus also inhibited the immunosuppressive activity of MDSCs in IFN-β promoter stimulator-1 knockout (KO) mice and in wild-type mice. In contrast, the immunosuppressive activity of MDSCs in TLR-3 KO mice was not significantly altered by reovirus treatment. The activation levels of CD4+ and CD8+ T cells were significantly lower in TLR3 KO mice than in wild-type mice after reovirus administration. These results indicate that reovirus inhibits the immunosuppressive activity of MDSCs in a TLR3, but not IFN-β promoter stimulator-1, signaling-dependent manner.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29555782     DOI: 10.4049/jimmunol.1700435

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.

Authors:  Devalingam Mahalingam; Grey A Wilkinson; Kevin H Eng; Paul Fields; Patrick Raber; Jennifer L Moseley; Karol Cheetham; Matt Coffey; Gerard Nuovo; Pawel Kalinski; Bin Zhang; Sukeshi Patel Arora; Christos Fountzilas
Journal:  Clin Cancer Res       Date:  2019-11-06       Impact factor: 12.531

2.  Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma.

Authors:  Sisi Liu; Mingxin Li; Fengqiao Sun; Junwen Zhang; Fusheng Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-28       Impact factor: 4.322

3.  Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.

Authors:  Laura Evgin; Tim Kottke; Jason Tonne; Jill Thompson; Amanda L Huff; Jacob van Vloten; Madelyn Moore; Josefine Michael; Christopher Driscoll; Jose Pulido; Eric Swanson; Richard Kennedy; Matt Coffey; Houra Loghmani; Luis Sanchez-Perez; Gloria Olivier; Kevin Harrington; Hardev Pandha; Alan Melcher; Rosa Maria Diaz; Richard G Vile
Journal:  Sci Transl Med       Date:  2022-04-13       Impact factor: 19.319

Review 4.  Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection.

Authors:  Tarryn Bourhill; Yoshinori Mori; Derrick E Rancourt; Maya Shmulevitz; Randal N Johnston
Journal:  Viruses       Date:  2018-08-11       Impact factor: 5.048

Review 5.  Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.

Authors:  Andy S Ding; Denis Routkevitch; Christina Jackson; Michael Lim
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

6.  oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.

Authors:  Wen Zhang; Xiao Hu; Jing Liang; Yujie Zhu; Beibei Zeng; Lin Feng; Changyun Zhao; Shangmei Liu; Binlei Liu; Kaitai Zhang
Journal:  Mol Ther Oncolytics       Date:  2020-01-11       Impact factor: 7.200

Review 7.  Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer.

Authors:  Hongyue Zhou; Mengyu Jiang; Hongyan Yuan; Weihua Ni; Guixiang Tai
Journal:  Oncol Lett       Date:  2020-12-24       Impact factor: 2.967

Review 8.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

Review 9.  Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.

Authors:  Bin Zhang; Ping Cheng
Journal:  Mol Cancer       Date:  2020-11-10       Impact factor: 27.401

Review 10.  Past, Present and Future of Oncolytic Reovirus.

Authors:  Louise Müller; Robert Berkeley; Tyler Barr; Elizabeth Ilett; Fiona Errington-Mais
Journal:  Cancers (Basel)       Date:  2020-10-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.